Evolving role of serum biomarkers in the management of ovarian cancer

Women's Health

Volumn 2, Issue 1, 2006, Pages 141-158

  Gadducci, Angiolo ^a   Cosio, Stefania ^a   Zanca, Giulia ^a   Genazzani, Andrea Riccardo ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Cancer antigen 125; Cytokine; Epithelial ovarian cancer; Glycoprotein antigen; Kallikrein; Lisophosphatidic acid; Proteomics; Tumor marker; Vascular endothelial growth factor

Indexed keywords

ANGIOGENIC FACTOR; BIOLOGICAL MARKER; CA 125 ANTIGEN; CARBOPLATIN; CYTOKERATIN; CYTOKINE; CYTOKINE RECEPTOR; D DIMER; DOCETAXEL; FIBRIN DEGRADATION PRODUCT; GLYCOPROTEIN; KALLIKREIN; LYSOPHOSPHATIDIC ACID; MONOCLONAL ANTIBODY; PACLITAXEL; PLATINUM DERIVATIVE; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; TAXANE DERIVATIVE; TOPOTECAN; TUMOR MARKER; VASCULOTROPIN;

ANTIGEN EXPRESSION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RECURRENCE; CANCER SCREENING; DIAGNOSTIC ACCURACY; DRUG MECHANISM; FOLLOW UP; HUMAN; IN VITRO STUDY; IN VIVO STUDY; OVARY CANCER; PATIENT MONITORING; POSTMENOPAUSE; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEOMICS; REVIEW; ULTRASOUND;

EID: 33646769316     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/17455057.2.1.141     Document Type: Review

References (157)

1. Bell DA: Origins and molecular pathology of ovarian cancer. Mod. Pathol. 18(Suppl. 2), S19-S32 (2005).
2. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ: Cancer statistics, 2003. CA Cancer J. Clin. 53, 5-26 (2003).
3. Heintz APM, Odicino F, Maisonneuve P et al.: Carcinoma of the ovary. J. Epidemiol. Biostat. 6, 107-138 (2001).
4. Jacobs I, Bast RC Jr: The CA 125 tumor-associated antigen: a review of the literature. Hum. Reprod. 4, 1-12 (1989).
5. Bast RC Jr, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB: CA 125: the past and the future. Int. J. Biol. Markers 13, 179-187 (1998).
6. Zeillemaker AM, Verbrugh HA, Hoynck van Papendrecht AA, Leguit P: CA 125 secretion by peritoneal mesothelial cells. J. Clin. Pathol. 47, 263-265 (1994).
7. Gadducci A, Ferdeghini M, Prontera C et al.: The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: relevance for differential diagnosis. Gynecol. Oncol. 44, 147-154 (1992).
8. Zannoni GF, Gallotta V, Legge F, Tarquini E, Scambia G, Ferrandina G: Pseudo-Meigs' syndrome associated with malignant struma ovarii: a Case report. Gynecol. Oncol. 94, 226-228 (2004).
9. Todo Y, Sakuragi N, Nishida R et al.: Combined use of magnetic resonance imaging, CA 125 assay, histologic type, and histologic grade in the prediction of lymph node metastasis in endometrial carcinoma. Am. J. Obstet. Gynecol. 188, 1265-1272 (2003).
10. Bender DP, Sorosky JI, Buller RE, Sood AK: Serum CA 125 is an independent prognostic factor in cervical adenocarcinoma. Am. J. Obstet. Gynecol. 189, 113-117 (2003).
11. Homma S, Satoh H, Kagohashi K, Fujiwara M, Kamma H, Sekizawa K: Production of CA 125 by human lung cancer cell lines. Clin. Exp. Med. 4, 139-141 (2004).
12. Allen GW, Forouzannia A, Bailey HH, Howard SP: Non-Hodgkin's lymphoma presenting as a pelvic mass with elevated CA- 125. Gynecol. Oncol. 94, 811-813 (2004).
13. Jacobs I, Davies AP, Bridges J et al.: Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. Br. Med. J. 306, 1030-1034 (1993).
14. Bast RC Jr, Siegal FP, Runowicz C et al.: Elevation of serum CA125 prior to diagnosis of an epithelial ovarian carcinoma. Gynecol. Oncol. 22, 115-120 (1985).
15. Pauler DK, Menon U, McIntosh M, Symecko HL, Skates SJ, Jacobs IJ: Factors influencing serum CA125II levels in healthy postmenopausal women. Cancer Epidemiol. Biomarkers Prev. 10, 489-493 (2001).
16. Menon U, Talaat A, Rosenthal AN et al.: Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening. Br. J. Obstet. Gynecol. 107, 165-169 (2000).
17. Fung MF, Bryson P, Johnston M, Chambers A, Cancer Care Ontario Practice Guidelines Initiative Gynecology Cancer Disease Site Group: Screening postmenopausal women for ovarian cancer: a systematic review. J. Obstet. Gynaecol. Can. 26, 717-728 (2004).
18. Modugno F, Ovarian Cancer and High-Risk Women Symposium Presenters: Ovarian cancer and high-risk women - implications for prevention, screening, and early detection. Gynecol. Oncol. 91, 15-31 (2003).
19. Knudsen UB, Tabor A, Mosgaard B et al.: Management of ovarian cysts. Acta Obstet. Gynecol. Scand. 83, 1012-1021 (2004).
20. Gadducci A, Cosio S, Carpi A, Niccolini A, Genazzani AR: Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Biomed. Pharmacother. 58, 24-38 (2004).
21. Maggino T, Gadducci A, D'Addario V et al.: Prospective multi-center study on CA 125 in postmenopausal pelvic masses. Gynecol. Oncol. 54, 117-123 (1994).
22. Schutter EM, Kenemans P, Sohn C et al.: Diagnostic value of pelvic examination, ultrasound, and serum CA 125 in postmenopausal women with a pelvic mass. An international multicenter study. Cancer 74, 1398-1406 (1994).
23. Roman LD, Muderspach LI, Stein SM, Laifer-Narin S, Groshen S, Morrow CP: Pelvic examination, tumor marker level, and gray-scale and Doppler sonography in the prediction of pelvic cancer. Obstet. Gynecol. 89, 493-500 (1997).
24. Morgante G, la Marca A, Ditto A, De Leo V: Comparison of two malignancy risk indices based on serum CA125, ultrasound score and menopausal status in the diagnosis of ovarian masses. Br. J. Obstet. Gynaecol. 106, 524-527 (1999).
25. Manjunath AP, Pratapkumar, Sujatha K, Vani R: Comparison of three risk of malignancy indices in evaluation of pelvic masses. Gynecol. Oncol. 81, 225-229 (2001).
26. Timmerman D, Bourne TH, Tailor A et al.: A comparison of methods for preoperative discrimination between malignant and benign adnexal masses: the development of a new logistic regression model. Am. J. Obstet. Gynecol. 181, 57-65 (1999).
27. Aslam N, Banerjee S, Carr JV, Savvas M, Hooper R, Jurkovic D: Prospective evaluation of logistic regression models for the diagnosis of ovarian cancer. Obstet. Gynecol. 96, 75-80 (2000).
28. ACOG Committee Opinion on Gynecologic Practice: The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer. Gynecol. Oncol. 87, 237-239 (2002).
29. Im SS, Gordon AN, Buttin BM et al.: Validation of referral guidelines for women with pelvic masses. Obstet. Gynecol. 105, 35-41 (2005).
30. Eltabbakh GH, Mount SL, Beatty B, Simmons-Arnold L, Cooper K, Morgan A: Factors associated with cytoreducibility among women with ovarian carcinoma. Gynecol. Oncol. 95, 377-383 (2004).
31. Brand E, Lidor Y: The decline of CA 125 level after surgery reflects the size of residual ovarian cancer. Obstet. Gynecol. 81, 29-32 (1993).
32. Yedema CA, Kenemans P, Thomas CM et al.: CA 125 serum levels in the early postoperative period do not reflect tumor reduction obtained by cytoreductive surgery. Eur. J. Cancer 29A, 966-971 (1993).
33. Gadducci A, Landoni F, Maggino T, Sartori E, Zola P, Fanucchi A: The relationship between postoperative decline of serum CA 125 levels and size of residual disease after initial surgery in patients with advanced ovarian cancer: a CTF study. Gynecol. Oncol. 63, 234-237 (1996).
34. Gadducci A, Zola P, Landoni F et al.: Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study. Gynecol. Oncol. 58, 42-47 (1995).
35. Colakovic S, Lukic V, Mitrovic L, Jelic S, Susnjar S, Marinkovic J: Prognostic value of CA125 kinetics and half-life in advanced ovarian cancer. Int. J. Biol. Markers 15, 147-152 (2000).
36. van Dalen A, Favier J, Burges A et al.: Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients. Gynecol. Oncol. 79, 444-450 (2000).
37. Tate S, Hirai Y, Takeshima N, Hasumi K: CA125 regression during neoadjuvant chemotherapy as an independent prognostic factor for survival in patients with advanced ovarian serous adenocarcinoma. Gynecol. Oncol. 96, 143-149 (2005).
38. Marth C, Zeimet AG, Widschwendter M et al.: Paclitaxel- and docetaxel-dependent activation of CA 125 expression in human ovarian carcinoma cells. Cancer Res. 57, 3818-3822 (1997).
39. Bonfrer JM, Linders TC, Hageman PC, Hilkens JG, Korse CM, Molthoff CF: Effect of paclitaxel (Taxol) on CA 125 expression and release by ovarian cancer cell lines. Tumor Biol. 18, 232-240 (1997).
40. Tsuda H, Hashiguchi Y, Nakata S et al.: CA 125 regression rate to predict overall survival differ between paclitaxel-containing regimen and nonpaclitaxel regimen in patients with advanced ovarian cancer. Int. J. Gynecol. Cancer 12, 435-437 (2002).
41. Bridgewater JA, Nelstrop AE, Rustin GJ, Gore ME, McGuire WP, Hoskins WJ: Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel. J. Clin. Oncol. 17, 501-508 (1999).
42. Gadducci A, Cosio, S, Fanucchi A, Negri S, Cristofani R, Genazzani AR: The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma. Gynecol. Oncol. 93, 131-136 (2004).
43. Fioretti P, Gadducci A, Ferdeghini M et al.: The concomitant determination of different serum tumor markers in epithelial ovarian cancer: relevance for monitoring the response to chemotherapy and follow-up of patients. Gynecol. Oncol. 44, 155-160 (1992).
44. Bast RC Jr, Klug TL, Schaetzl E et al.: Monitoring human ovarian carcinoma with a combination of CA 125, CA 19-9 and carcinoembryonic antigen. Am. J. Obstet. Gynecol. 149, 553-559 (1984).
45. Gadducci A, Sartori E, Zola P et al.: Serum CA125 assay in the early diagnosis of recurrent epithelial ovarian cancer: A CTF study. Oncol. Rep. 3, 301-303 (1996).
46. Rustin GJS, Nelstrop AE, Tuxen MK, Lambert HE: Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann. Oncol. 7, 361-364 (1996).
47. Rustin GJ, Nelstrop AE, Bentzen SM, Bond SJ, McClean P: Selection of active drugs for ovarian cancer based on CA- 125 and standard response rates in Phase II trials. J. Clin. Oncol. 18,1733-1739 (2000).
48. Rustin GJ: Use of CA- 125 to assess response to new agents in ovarian cancer trials. J. Clin. Oncol. 21 (Suppl. 10), 187-193 (2003).
49. Therasse P, Arbuck SG, Eisenhauer EA et al.: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl Cancer Inst. 92, 205-216 (2000).
50. Gronlund B, Hogdall C, Hilden J, Engelholm SA, Hogdall EV, Hansen HH: Should CA-125 response criteria be preferred to Response Evaluation Criteria In Solid Tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma? J. Clin. Oncol. 22, 4051-4058 (2004).
51. Woolas RP, Xu FJ, Jacobs IJ et al.: Elevation of multiple serum markers in patients with stage I ovarian cancer. J. Natl Cancer Inst. 85, 1748-1751 (1993).
52. van Haaften-Day C, Shen Y, Xu F et al.: OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal. Cancer92, 2837-2844 (2001).
53. Xu FJ, Yu YH, Daly L et al.: OVX1 radioimmunoassay complements CA- 125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures. J. Clin. Oncol. 11, 1506-1510 (1993).
54. Dehn H, Hogdall EV, Johansen JS et al.: Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer. Acta Obstet. Gynecol. Scand. 82, 287-293 (2003).
55. Hogdall EV, Johansen JS, Kjaer SK et al.: High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival. Oncol. Rep. 10, 1535-1538 (2003).
56. DuPont J, Tanwar MK, Thaler HT et al.: Early detection and prognosis of ovarian cancer using serum YKL-40. J. Clin. Oncol. 22, 3330-3339 (2004).
57. Kainz C, Sliutz G, Mustafa G et al.: Cytokeratin subunit 19 measured by CYFRA 21-1 assay in the follow-up of cervical cancer. Gynecol. Oncol. 56, 402-405 (1995).
58. Templer C, Hefler L, Heinzl H et al.: CYFRA 21 -1 serum levels in women with adnexal masses and inflammatory diseases. Br. J. Cancer 78, 1108-1112 (1998).
59. Gadducci A, Ferdeghini M, Cosio S, Fanucchi A, Cristofani R, Genazzani AR: The clinical relevance of serum CYFRA 21-1 assay in patients with ovarian cancer. Int. J. Gynecol. Cancer 11, 277-282 (2001).
60. Yousef GM, Diamandis EP: The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr. Rev. 22, 184-204 (2001).
61. Clements J, Hooper J, Dong Y, Harvey T: The expanded human kallikrein (KLK) gene family: genomic organisation, tissue-specific expression and potential functions. Biol. Chem. 382, 5-14 (2001).
62. Yousef GM, Fracchioli S, Scorilas A et al.: Steroid hormone regulation and prognostic value of the human kallikrein gene 14 in ovarian cancer. Am. J. Clin. Pathol. 119, 346-355. (2003).
63. Shvartsman HS, Lu KH, Lee J et al.: Overexpression of kallikrein 10 in epithelial ovarian carcinomas. Gynecol. Oncol. 90, 44-50 (2003).
64. Yousef GM, Kyriakopoulou LG, Scorilas A et al.: Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favourable prognostic marker. Cancer Res. 61, 7811-7818 (2001).
65. Dong Y, Kaushal A, Bui L et al.: Human kallikrein 4 (KLK4) is highly expressed in serous ovarian carcinomas. Clin. Cancer Res. 7, 2363-2371 (2001).
66. Obiezu CV, Scorilas A, Katsaros D et al.: Higher human kallikrein gene 4 (KLK4) expression indicates poor prognosis of ovarian cancer patients. Clin. Cancer Res. 7, 2380-2386 (2001).
67. Kim H, Scorilas A, Katsaros D et al.: Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer. Br. J. Cancer 84, 643-650 (2001).
68. Yousef GM, Scorlias A, Katsaros D et al.: Prognostic value of the human kallikrein gene 15 expression in ovarian cancer. J. Clin. Oncol. 21, 3119-3126 (2003).
69. Diamandis EP, Borgono CA, Scorilas A, Harbeck N, Dorn J. Schmitt M: Human kallikrein 11: an indicator of favorable prognosis in ovarian cancer patients. Clin. Biochem. 37, 823-829 (2004).
70. Ni X, Zhang W, Huang KC et al.: Characterisation of human kallikrein 6/ protease M expression in ovarian cancer. Br. J. Cancer 91, 725-731 (2004).
71. Yousef GM, White NMA, Kurlender L et al.: The kallikrein gene 5 splice variant 2 is a new biomarker for breast and ovarian cancer and ovarian cancer. Tumor Biol. 25, 221-227 (2004).
72. Diamandis EP, Yousef GM, Soosaipillai AR, Bunting P: Human kallikrein 6 (zyme/protease M/neurosin): a new serum biomarker of ovarian carcinoma. Clin. Biochem. 33, 579-583 (2000).
73. Diamandis EP, Scorilas A, Fracchioli S et al.: Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J. Clin. Oncol. 21, 1035-1043 (2003).
74. Luo LY, Katsaros D, Scorilas A et al.: The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Cancer Res. 63, 807-811 (2003).
75. Diamandis EP, Okui A, Mitsui S et al.: Human kallikrein 11: a new biomarker of prostate and ovarian carcinoma. Cancer Res. 62, 295-300 (2002).
76. Santin AD, Diamandis EP, Bellone S et al.: Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancer. Clin. Cancer Res. 11, 3320-3325 (2005).
77. Devoogdt N, Hassanzadeh, Ghassabeh G et al.: Secretory leukocyte protease inhibitor promotes the tumorigenic and metastatic potential of cancer cells. Proc. Natl Acad. Sci. USA 100, 5778-5782 (2003).
78. Garver RI Jr, Goldsmith KT, Rodu B, Hu PC, Sorscher EJ, Curiel DT: Strategy for achieving selective killing of carcinomas. Gene Ther. 1, 46-50 (1994).
79. Tsukishiro S, Suzumori N, Nishikawa H, Arakawa A, Suzumori K: Use of serum secretory leukocyte protease inhibitor levels in patients to improve specificity of ovarian cancer diagnosis. Gynecol. Oncol. 96, 516-519 (2005).
80. Scambia G, Testa U, Benedetti Panici P et al.: Prognostic significance of Interleukin-6 serum levels in patients with ovarian cancer. Br. J. Cancer 71, 354-356 (1995).
81. Tempfer C. Zeisier H, Sliutz G, Haeusler G, Hanzal E, Kainz C: Serum evaluation of interleukin-6 in ovarian cancer patients. Gynecol. Oncol. 66, 27-30 (1997).
82. Maccio A, Lai P, Santona MC, Pagliara L, Melis GB, Mantovani G: High serum levels of soluble IL-2 receptor, cytokines, and C reactive protein correlate with impairment of T-cell response in patients with advanced epithelial ovarian cancer. Gynecol. Oncol. 69, 248-252 (1998).
83. Foti E, Ferrandina G, Martucci R et al.: IL-6, M-CFS and IAP cytokines in ovarian cancer: simultaneous assessment of serum levels. Oncology 57, 211-215 (1999).
84. Gadducci A, Ferdeghini M. Castellani C et al.: Serum macrophage colony- stimulating factor (M-CSF) levels in patients with epithelial ovarian cancer. Gynecol. Oncol. 70, 111-114 (1998).
85. Skates SJ, Horick N, Yu Y et al.: Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J. Clin. Oncol. 22, 4059-4066 (2004).
86. Scambia G, Foti E, Ferrandina G et al.: Prognostic role of immunosuppressive acidic protein in advanced ovarian cancer. Am. J. Obstet. Gynecol. 175, 1606-1610 (1996).
87. Gadducci A, Ferdeghini M, Malagnino G et al.: Elevated serum levels of neopterin and soluble interleukin-2 receptor in patients with ovarian cancer. Gynecol. Oncol. 52, 386-391 (1994).
88. Zeimet AG, Natoli C, Herold M et al.: Circulating immunostimulatory protein 90K and soluble interleukin-2-receptor in human ovarian cancer. Int. J. Cancer 68, 34-38 (1996).
89. Gebauer G, Rieger M, Jager W, Lang N: Prognostic relevance of soluble interleukin-2 receptors in patients with ovarian tumors. Anticancer Res. 19, 2509-2511 (1999).
90. Sedlaczek P, Frydecka I, Gabrys M, Van Dalen A, Einarsson R, Hariozinska A: Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma. Cancer 95, 1886-1893 (2002).
91. Grosen EA, Granger GA, Gatanaga M et al.: Measurement of the soluble membrane receptors for tumor necrosis factor and lymphotoxin in the sera of patients with gynecologic malignancy. Gynecol. Oncol. 50, 68-77 (1993).
92. Gadducci A, Ferdeghini M, Castellani C et al.: Serum levels of tumor necrosis factor (TNF), soluble receptors for TNF (55- and 75-kDa sTNFr), and soluble CD14 (sCD14) in epithetial ovarian cancer. Gynecol. Oncol. 58, 184-188 (1995).
93. Onsrud M, Shabana A, Austgulen R: Soluble tumor necrosis factor receptors and CA 125 in serum as markers for epithelial ovarian cancer. Tumor Biol. 17, 90-96 (1996).
94. Burger RA, Darcy KM, DiSaia PJ et al.: Association between serum levels of soluble tumor necrosis factor receptors/CA 125 and disease progression in patients with epithelial ovarian malignancy: a gynecologic oncology group study. Cancer 101, 106-115 (2004).
95. Owen-Schaub LB, Angelo LS, Radinsky R, Ware CF, Gesner TG, Bartos DP: Soluble Fas/APO-1 in tumor cells: a potential regulator of apoptosis? Cancer Lett. 94, 1-8 (1995).
96. Pignataro L, Arisi E, Sambataro G, Corsi MM: Soluble Fas (sFas) and soluble Fas ligand (sFas-L) balance in laryngeal carcinoma before and after surgical treatment. Surg. Oncol. 83, 112-115 (2003).
97. Nagata S, Golstein P: The Fas death factor. Science 267, 1449-1456 (1995).
98. Konno R, Takano T, Sato S, Yajima A: Serum soluble fas level as a prognostic factor in patients with gynecologic malignancies. Clin. Cancer Res. 6, 3576-3580 (2000).
99. Heiler L, Mayerhofer K, Nardi A, Reinthaller A, Kainz C, Tempfer C: Serum soluble Fas levels in ovarian cancer. Obstet. Gynecol. 96, 65-69 (2000).
100. Akhmedkhanov A, Lundin E, Gulier S et al.: Circulating soluble Fas levels and risk of ovarian cancer. BMC Cancer 3, 33 (2003).
101. Robertson DM, Pruysers E, Burger HG, Jobling T, McNeilage J, Healy D: Inhibins and ovarian cancer. Mol. Cell. Endocrinol. 225, 65-71 (2004).
102. Healy DL, Burger HG, Marners P et al.: Elevated serum inhibin concentrations in postmenopausal women with ovarian tumors. N. Engl. J. Med. 329, 1539-1542 (1993).
103. Phocas I, Sarandakou A, Sikiotis K, Rizos D, Kalambokis D, Zourias PA: A comparative study of serum α-βA immunoreactive inhibin and tumor-associated antigens CA125 and CEA in ovarian cancer. Anticancer Res. 16, 3827-3831 (1996).
104. Lambert-Messerlian GM, Steinhoff M, Zheng W et al.: Multiple immunoreactive inhibin proteins in serum from postmenopausal women with epithelial ovarian cancer. Gynecol. Oncol. 65, 512-516 (1997).
105. Robertson DM, Cahir N, Burger HG et al.: Combined inhibin and CA125 assays in the detection of ovarian cancer. Clin. Chem. 45, 651-658 (1999).
106. Robertson DM, Stephenson T, Pruysers E et al.: Characterization of inhibin forms and their measurement by an inhibin alpha-subunit ELISA in serum from postmenopausal women with ovarian cancer. J. Clin. Endocrinol. Metab. 87, 816-824 (2002).
107. Frias AE Jr, Li H, Keeney GL, Podratz KC, Woodruff TK: Preoperative serum levels of inhibin A is an independent prognostic factor for the survival of postmenopausal women with epithelial ovarian carcinoma. Cancer 85, 465-471 (1999).
108. Gadducci A, Viacava P, Cosio S et al.: Vascular endothelial growth factor (VEGF) expression in primary tumors and peritoneal metastases from patients with advanced ovarian carcinoma. Anticancer Res. 23, 3001-3008 (2003).
109. Raspollini MR, Castiglione F, Garbini F et al.: Correlation of epidermal growth factor receptor expression with tumor microdensity vessels and with vascular endothelial growth factor expression in ovarian carcinoma. Int. J. Surg. Pathol. 13, 135-142 (2005).
110. Yamamoto S, Konishi I, Mandai M et al.: Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br. J. Cancer 76, 1221-1227 (1997).
111. Tempfer C, Obermair A, Hefler L, Haeusler G, Gitsch G, Kainz C: Vascular endothelial growth factor serum concentrations in ovarian cancer. Obstet. Gynecol. 92, 360-363 (1998).
112. Chen CA, Cheng WF, Lee CN et al.: Serum vascular endothellal growth factor in epithelial ovarian neoplasms: correlation with patient survival. Gynecol. Oncol. 74, 235-240 (1999).
113. Gadducci A, Ferdeghini M, Fanucchi A et al.: Serum preoperative vascular endothelial growth factor (VEGF) in epithelial ovarian cancer: relationship with prognostic variables and clinical outcome. Anticancer Res. 19, 1401-1405 (1999).
114. Cooper BC, Ritchie IM, Broghammer CL et al.: Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clin. Cancer Res. 8, 3193-3197 (2002).
115. Li L, Wang L, Zhang W et al.: Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer. Anticancer Res. 24, 1973-1979 (2004).
116. Alvarez Secord A, Sayer R, Snyder SA et al.: The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer. Gynecol. Oncol. 94, 74-79 (2004).
117. Reynolds K, Farzaneh F, Collins WP et al.: Association of ovarian malignancy with expression of platelet-derived endothelial cell growth factor. J. Natl. Cancer Inst. 86, 1234-1238 (1994).
118. Sumizawa T, Furukawa T, Haraguchi M et al: Thymidine phosphorylase activity associated with platelet-derived endothelial cell growth factor. J. Biochem. 114, 9-14 (1993).
119. Haraguchi M, Miyadera K, Uemura K et al.: Angiogenic activity of enzymes. Nature 368, 198 (1994).
120. Miszczak-Zaborska E, Wojcik-Krowiranda K, Kubiak R, Bienkiewicz A, Bartkowiak J: The activity of thymidine phosphorylase as a new ovarian tumor marker. Gynecol. Oncol. 94, 86-92 (2004).
121. Gadducci A, Baicchi U, Marrai R, Ferdeghini M, Bianchi R, Facchini V: Preoperative evaluation of D-dimer and CA 125 levels in differentiating benign from malignant ovarian masses. Gynecol. Oncol. 60, 197-202 (1996).
122. von Tempelhoff GF, Dietrich M, Niemann F, Schneider D, Hommel G, Heilmann L: Blood coagulation and thrombosis in patients with ovarian malignancy. Thromb. Haemost. 77, 456-461 (1997).
123. Gadducci A, Marrai R, Baicchi U et al.: Preoperative D-dimer plasma assay is not a predictor of clinical outcome for patients with advanced ovarian cancer. Gynecol. Oncol. 66, 85-88 (1997).
124. den Ouden M, Ubachs JM, Stoot JE, van Wersch JW: Thrombin-antithrombin III and D-dimer plasma levels in patients with benign or malignant ovarian tumors. Scand. J. Clin. Lab. Invest. 58, 555-559 (1998).
125. Koh SC, Tham KF, Razvi K et al.: Hemostatic and fibrinolytic status in patients with ovarian cancer and benign ovarian cysts: could D-dimer and antithrombin III levels be included as prognostic markers for survival outcome? Clin. Appl. Thromb. Hemost. 7, 141-148 (2001).
126. Gadducci A, Marrai R, Baicchi U et al.: The measurement of plasma D-dimer (DD) levels in the follow-up of patients with ovarian cancer. Anticancer Res. 15, 2683-2686 (1995).
127. Sayers TJ, Murphy WJ: Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy. Cancer Immunol. Immunother. (2005) (Epub ahead of print).
128. Lancaster JM, Sayer R, Blanchette C et al.: High expression of tumor necrosis factor-related apoptosis-inducing ligand is associated with favorable ovarian cancer survival. Clin. Cancer Res. 9, 762-766 (2003).
129. Gaits F, Fourcade o, Le BaLLe F et al.: Lysophosphatidic acid as a phospholipid mediator: pathways of synthesis. FEBS Lett. 410, 54-58 (1997).
130. Shen Z, Belinson J, Morton RE, Xu Y, Xu Y: Phorbol 12-myristate 13-acetate stimulates lysophosphatidic acid secretion from ovarian and cervical cancer cells but not from breast or leukemia cells. Gynecol. Oncol. 71, 364-368 (1998).
131. Eder AM, Sasagawa T, Mao M, Aoki J, Mills GB: Constitutive and lysophosphatidic acid (LPA)-induced LPA production: role of phospholipase D and phospholipase A2. Clin. Cancer Res. 6, 2482-2491 (2000).
132. Xu Y, Shen Z, Wiper DW et al.: Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 280, 719-723 (1998).
133. Kang YC, Kim KM, Lee KS et al.: Serum bioactive lysophospholipids prevent TRAIL-induced apoptosis via PI3K/Akt-dependent cFLIP expression and Bad phosphorylation. Cell Death Differ 11, 1287-1298 (2004).
134. Meng Y, Kang S, So J, Reierstad S, Fishman DA: Translocation of Fas by LPA prevents ovarian cancer cells from antiFas-induced apoptosis. Gynecol. Oncol. 96, 462-469 (2005).
135. So J, Navari J, Wang FQ, Fishman DA: Lysophosphatidic acid enhances epithelial ovarian carcinoma invasion through the increased expression of interleukin-8. Gynecol. Oncol. 95, 314-322 (2004).
136. Sutphen R, Xu Y, Wilbanks GD et al.: Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 13, 1185-1191 (2004).
137. Baker DL, Morrison P, Miller B et al.: Plasma lysophosphatidic acid concentration and ovarian cancer. JAMA 287, 3081-3082 (2002).
138. Petricoin EF, Ardekani AM, Hitt BA et al.: Use of proteomic patterns to identify ovarian cancer. Lancet 359, 572-577 (2002).
139. Herbert BR, Sanchez J-C, Bini L: Two-dimensional electrophoresis: the state of the art and future directions in proteome research. In: Proteome research: New Frontiers in Functional Genomics. Wilkens MR, Williams KL, Aappel RD, Hochstrasser DF (Eds). Springer-Verlag, NY, USA, 13-30 (1997).
140. Richter R, Schulz-Knappe P, Schrader M et al.: Composition of the peptide fraction in human blood plasma: database of circulating human peptides. J. Chromatogr. B. Biomed. Sci. Appl. 726, 25-35 (1999).
141. Simone NL, Paweletz CP, Charboneau L, Petricoin ER III, Liotta LA: Laser capture microdissection: beyond functional genomics to proteomics. Mol. Diagn. 5, 301-307 (2000).
142. Bichsel VE, Liotta LA, Petricoin EF III: Cancer proteomics: from biomarker discovery to signal pathway profiling. Cancer J. 7, 69-78 (2001).
143. Rai AJ, Zhang Z, Rosenzweig J et al.: Proteomic approaches to tumor marker discovery. Identification of biomarkers for ovarian cancer. Arch. Pathol. Lab. Med. 126, 1518-1526 (2002).
144. Ahmed N, Barker G, Oliva KT et al.: Proteomic-based identification of haptoglobin-1 precursor as a novel circulating biomarker of ovarian cancer. Br. J. Cancer 9l, 129-140 (2004).
145. Posadas EM, Davidson B, Kohn EC: Proteomics and ovarian cancer: implications for diagnosis and treatment: a critical review of the recent literature. Curr. Opin. Oncol. 16, 478-484 (2004).
146. Rapkiewicz AV, Espina V, Petricoin EF III, Liotta LA: Biomarkers of ovarian tumors Eur. J. Cancer 40, 2604-2612 (2004).
147. Posadas EM, Simpkins E, Liotta LA, MacDonald C, Kohn EC: Proteomic analysis for the early detection and rational treatment of cancer-realistic hope? Ann. Oncol. 16, 16-22 (2005).
148. Li L, Tang H, Wu Z et al: Data mining techniques for cancer detection using serum proteomic profiling. Artif. Intell. Med. 32, 71-83 (2004).
149. Zhang Z, Bast RC Jr, Yu Y et al.: Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 64, 5882-5890 (2004).
150. Matrisian LM, Sledge GW Jr, Mohia S: Extracellular proteolysis and cancer: meeting summary and future directions. Cancer Res. 63, 6105-6109 (2003).
151. Roberts D, Williams SJ, Cvetkovic D et al.: Decreased expression of retinol-binding proteins is associated with malignant transformation of the ovarian surface epithelium. DNA Cell Biol. 21, 11-19 (2002).
152. Schweigert FJ, Sehouli J: Transthyretin, a biomarker for nutritional status and ovarian cancer. Cancer Res. 65, 1114 (2005).
153. Mehta AI, Ross S, Lowenthal MS et al.: Biomarker amplification by serum carrier protein binding. Dis. Markers 19, 1-10 (2003-2004).
154. Lowenthal MS, Mehta AI, Frogale K et al.: Analysis of albumin-associated peptides and proteins from ovarian cancer patients. Clin. Chem. 51(10), 1933-1945 (2005).
155. Schmitt M, Harbeck N, Daidone MG et al.: Identification, validation, and clinical implementation of tumor-associated biomarkers to improve therapy concepts, survival, and quality of life of cancer patients: tasks of the Receptor and Biomarker Group of the European Organization for Research and Treatment of Cancer. Int. J. Oncol. 25, 1397-1406 (2004).
156. Duffy MJ: Evidence for the clinical use of tumor markers. Ann. Clin. Biochem. 41, 370-377 (2004).
157. Ransohoff DF: Lessons from controversy: ovarian cancer screening and serum proteomics. J. Natl Cancer Inst. 97, 315-319 (2005).